`
`FDA Approves Expanded Indication for Xibrom to Treat Pain Following Cataract Surgery Drugs.com MedNews
`
`FDA Approves Expanded Indication for Xibrom to
`Treat Pain Following Cataract Surgery
`
`IRVINE, Calif., January 30, 2006 ISTA Pharmaceuticals, Inc. today announced that the U.S. Food & Drug
`Administration (FDA) has approved ISTA's supplemental New Drug Application (sNDA) for Xibrom
` of pain
`(bromfenac ophthalmic solution) 0.09%, expanding Xibrom's indications to include the treatment
`following cataract surgery. Xibrom, a topical, twicedaily, nonsteroidal antiinflammatory solution (NSAID),
`was originally approved by the FDA in March 2005 for the treatment of ocular inflammation following cataract
`surgery . ISTA launched Xibrom in the U.S. during the second quarter of 2005.
`
`Vicente Anido, Jr., Ph.D., President and Chief Executive Officer of ISTA stated, "Since Xibrom's launch,
`prescriptions have grown rapidly, and the product has taken a lead position in our portfolio. We are excited
`to receive this additional approval from the FDA, which we believe will expand the use of our product and
`greatly facilitate our sales force initiatives reaching the market base of approximately 10,000 ophthalmologists
`in the U.S."
`
`About Xibrom and the U.S. Ophthalmic AntiInflammatory Market
`Xibrom (bromfenac ophthalmic solution) 0.09% is a sterile, topical, nonsteroidal antiinflammatory solution
`for the treatment of ocular inflammation and pain following cataract surgery. Senju Pharmaceuticals Co.
`Ltd. has marketed this product in Japan since 2000 with over 7.9 million uses since that time. ISTA acquired
`U.S. marketing rights for Xibrom in May 2002 under a license from Senju.
`
`ISTA completed two pivotal Phase III clinical studies of Xibrom in the United States. In these studies
`involving 527 patients, a statistically significant proportion of patients treated with Xibrom achieved treatment
`success, defined as the complete absence of ocular inflammation compared to those patients who received
`placebo. This effect was evident in the Xibrom group as early as day 3 following initiation of treatment.
`Furthermore, 75% of patients who experienced pain after cataract surgery were painfree within two days of
`being treated with Xibrom twice daily. In addition, 98% of patients experiencing pain after cataract surgery
`and receiving Xibrom twice daily were painfree within six days of treatment.
`
`The topical ophthalmic antiinflammatory market consists of steroids, NSAIDS and combination products.
`Based upon management estimates of sales and 2004 prescription data from IMS, U.S. sales in 2004 in this
`market were approximately $400 million, with total prescriptions of 8.6 million.
`
`Source: ISTA
`
`Posted: January 2006
`
`http://www.drugs.com/news/fdaapprovesexpandedindicationxibrompainfollowingcataractsurgery1703.html
`
`1/2
`
`Page 1 of 2
`
`SENJU EXHIBIT 2189
`LUPIN v. SENJU
`IPR2015-01097
`
`
`
`11/16/2015
`
`FDA Approves Expanded Indication for Xibrom to Treat Pain Following Cataract Surgery Drugs.com MedNews
`
`Make Your Holiday Party Sparkle with Unique Details and Personal
`Inspiration.
`What will inspire your holiday gettogether this year? Designer Justina Blakeney found great details on
`eBay to take her holiday party to the next level.
`
`Promoted by eBay
`
`View comments
`
`http://www.drugs.com/news/fdaapprovesexpandedindicationxibrompainfollowingcataractsurgery1703.html
`
`2/2
`
`Page 2 of 2